A Proof of Concept Study of the Safety and Efficacy of VIB7734 for the Treatment and Prevention of Acute Lung Injury (ALI) in Patients With SARS-CoV-2 Infection
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- The proportion of patients who achieve treatment success through Day 28, defined as avoidance of death and critical illness
研究概览
简要总结
The study aims to assess the potential benefit and evaluate the safety and tolerability of a single subcutaneous (SC) dose of VIB7734 in hospitalized patients with documented infection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) with pulmonary involvement. Subjects will be administered a single dose of VIB7734 injected under the skin, assessed for efficacy for 28 days and followed for an additional 42 days.
详细描述
This is a randomized, double-blind, placebo-controlled study intended to assess the potential benefit and evaluate the safety and tolerability of a single subcutaneous (SC) dose of VIB7734 in hospitalized patients with documented infection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) with pulmonary involvement. Efficacy will be assessed during the 28 days following a single administration of VIB7734. Safety will be assessed for 10 weeks following dosing. The pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of VIB7734 in patients with confirmed SARS-CoV-2 infections will also be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hospitalized with coronavirus disease 2019 (COVID-19) pneumonia confirmed by World Health Organization criteria.
- •Oxygen saturation ≤ 94% at room air or arterial partial pressure of oxygen/fraction of inspired oxygen < 300 mm Hg and > 200 mm Hg.
- •Negative influenza test.
- •Lymphocyte counts < 10^3/μL and the presence of at least one of the following markers of hyperinflammation within 1 day prior to VIB7734 administration:
- •Elevated high sensitivity C-reactive protein (hsCRP) > 50 mg/L
- •Ferritin > 500 ng/mL
- •Lactate dehydrogenase (LDH) > 300 U/L
- •D-dimers > 500 ng/mL
- •NOTE: Other protocol defined inclusion criteria apply
排除标准
- •Respiratory failure requiring mechanical ventilation.
- •In the opinion of the Investigator, progression to mechanical ventilation or death is imminent and inevitable within the next 24 hours.
- •Valid Do Not Intubate (DNI) or Do Not Resuscitate (DNR) order.
- •Anticipated duration of hospital stay < 72 hours.
- •History of allergy or hypersensitivity reaction to any component of the IP.
- •Participation in another clinical study with an IP within 4 weeks prior to Day 1 or within 5 half-lives of the IP, whichever is longer. (Participation in COVID-19 antiviral or antimalarial trials may be permitted after discussion with the Medical Monitor).
- •Liver cirrhosis or liver failure.
- •Known human immunodeficiency virus infection.
- •Known hepatitis B or known hepatitis C infection in the absence of a history of curative therapy.
- •Known or suspect active or latent tuberculosis infection.
- •Active bacterial, fungal, viral, or other infection (besides COVID-19).
- •Clinically significant cardiac disease within 6 months.
- •History of severely impaired respiratory function at baseline (not related to COVID-19) based on requirement for home oxygen of > 4 L/min or based on other medical history known to the Investigator.
- •History of cancer within 12 months of enrollment.
- •Receipt of chemotherapy, biologic immunomodulators (including JAK inhibitors), or immunosuppressive therapies within 8 weeks of enrollment, or receipt of rituximab or other B cell-depleting mAb therapy within 6 months.
- •NOTE: Other protocol defined exclusion criteria apply
研究组 & 干预措施
VIB7734 Dose
Participants will receive a single subcutaneous dose of VIB7734.
干预措施: VIB7734 (Drug)
Placebo
Participants will receive a single subcutaneous dose of placebo (saline) matched to single dose of VIB7734.
干预措施: Placebo (Drug)
结局指标
主要结局
The proportion of patients who achieve treatment success through Day 28, defined as avoidance of death and critical illness
时间窗: Day 1 (Baseline) through Day 28
Critical illness is defined by respiratory failure (requiring any of the following: endotracheal intubation, oxygen delivered by high flow nasal cannula, non-invasive positive pressure ventilation, extracorporeal membrane oxygenation or clinical diagnosis of respiratory failure) or shock (systolic blood pressure \< 90 mm Hg, or diastolic blood pressure \< 60 mm Hg, or requiring vasopressors)
次要结局
- Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent fatal and life-threatening SAEs, Treatment-emergent Serious Adverse Events(Day 1 (Baseline) through Day 70)
- Change in safety laboratory parameters(Day 1 (Baseline) through Day 70)